Brain Trust Advises US FDA On Aneurysm Device Trials
Executive Summary
To help figure out how intracranial aneurysm devices should be evaluated in clinical trials, US FDA brought together its Neurological Devices Advisory Panel. The experts answered questions ranging from safety and efficacy endpoints that should be taken into consideration to post-market study requirements.
You may also be interested in...
Neuro Panel Takeaways: Detailed Responses On Aneurysm Devices From US FDA Advisors
Point-by-point clinical trial recommendations from US FDA's Neurological Devices Advisory Panel at a recent meeting on intracranial aneurysm devices.
FDA's US-First Strategy: Device Center Sets Three-Year Goals
A new three-year plan to implement strategic priorities at US FDA's device center aims to make several broad improvements to the medtech ecosystem. Among them is improving staff incentives at the agency, creating more partnerships with industry and other stakeholders, and improving the center's processes to make it easier for novel medical devices to enter the US market.
Experts Recommend Requiring Randomized Trials For Flow Diverter PMAs
FDA's Neurological Devices Panel says sponsors should be required to conduct randomized controlled trials for aneurysm treatment devices such as flow diverters and should only be allowed to use performance goal studies as a last resort to support approval.